AC Immune – Discover Pharma

Welcome to Discover Pharma! Today is : October 23, 2026

AC Immune

Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune gets FDA Fast Track for Parkinson’s immunotherapy ACI-7104
AC Immune has received FDA Fast Track designation and IND [...]

August 12, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune advances Parkinson’s and Alzheimer’s pipeline with key clinical milestones ahead
AC Immune has outlined a series of clinical milestones expected [...]

August 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
AC Immune amends Lilly collaboration on Tau small molecules for Alzheimer’s disease
AC Immune has amended its collaboration agreement with Eli Lilly [...]

May 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764
AC Immune has initiated a Phase 1 trial of its [...]

May 5, 2026
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression
AC Immune SA has reported positive interim results from [...]

May 5, 2026

main menu

recent posts

get connected

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK